An observational study in Cytomegalovirus Infection Reactivation, sponsored by Anhui Provincial Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-06-04.
Sponsored by Anhui Provincial Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Cytomegalovirus Infections with a site in China — 8 open to participants now, 8 under way, none of them phase 3. Cytomegalovirus Infections · China.
Among the 23 studies in Cytomegalovirus Infections with a site in China, this one is the 8th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2024, is one of 12 observational ones, and was the 16th registered.
370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.
Browse Cytomegalovirus Infections studies →8 of the 23 studies in Cytomegalovirus Infections with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
WeiShi · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Chinese PLA General Hospital · Sites in China
Ages 14–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 1 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 60 is below the median of 150 across 93 observational studies indexed under Cytomegalovirus Infections.
Median enrollment 80 across the 11 interventional studies, 111 across the 12 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 23 have an industry lead sponsor. The 10 most frequent:
Anhui Provincial Hospital is the lead sponsor of 135 studies on the registry; 101 are open to participants now.
Anhui Provincial Hospital has 1 study filed under Cytomegalovirus Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Cytomegalovirus Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07569653WeiShiLetermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT. | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Cytomegalovirus Infections with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation
To explore the effect of letermovir prophylaxis on cytomegalovirus-specific and other lymphocyte subsets immune reconstitution post unrelated cord blood transplantation, and to analyze the potential mechanism and risk factors of late CMV reactivation after letermovir discontinuation.
The study consists 60 cases recipients of UCBT. All patients will receive letermovir prophylaxis within 0-28 days post UCBT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will be given Letermovir with a recommended dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine or according to clinical instructions) from +1 day to +100 days after UCBT.
Drug: Letermovir
Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.
Numbers of immune cells in peripheral blood
PBMCs from UCBT recipients were collected at 1 month, 2 month, 3 month, and 6 month and 12 month after HSCT, and tested for CMV-specific T cells, NK cells, T cells and other subsets.
Time frame: one year
CMV DNAemia
CMV DNAemia is defined as the detection of CMV DNA in samples of plasma, whole blood or isolated peripheral blood leukocyte.
Time frame: one year
Incidence of refractory CMV infection
Refractory CMV infection is defined as CMV viral load remaining at the same level or increasing despite appropriately doses of antiviral therapy for at least 2 weeks
Time frame: one year
late CMV reactivation
Late CMV reactivation is defined as reactivation that occurs 100 days post UCBT, which means reactivation after discontinuing LET prophylaxis.
Time frame: one year
Treatment-ralated mortality
Treatment-ralated mortality
Time frame: one year
Incidence of other viral infection and viral-associated disease
Other viral infection and viral-associated diseases including EBV, ADV, HHV-6, BKV and HSV
Time frame: one year
Overall survival
Overall survival
Time frame: one year
serum immunoglobulin assay
The serum levels of IgG, IgM, and IgA were measured
Time frame: 1,3,6,9 month post UCBT
Started May 2024 (actual). Primary completion is estimated for May 2026, 24 months after the start.
Of 30 observational studies under Cytomegalovirus Infections, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 61. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.